<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mediators Inflamm</journal-id><journal-title>Mediators of Inflammation</journal-title><issn pub-type="ppub">0962-9351</issn></journal-meta><article-meta><article-id pub-id-type="pmid">15770057</article-id><article-id pub-id-type="pmc">1781578</article-id><article-id pub-id-type="pii">S0962935104000572</article-id><article-id pub-id-type="doi">10.1155/S0962935104000572</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>No effects of ozonated autohemotherapy on inflammation response in hemodialyzed patients.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tylicki</surname><given-names>Leszek</given-names></name><email>leszek.tylicki@amg.gda.pl</email></contrib><contrib contrib-type="author"><name><surname>Biedunkiewicz</surname><given-names>Bogdan</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rachon</surname><given-names>Dominik</given-names></name></contrib><contrib contrib-type="author"><name><surname>Nieweglowski</surname><given-names>Tomasz</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hak</surname><given-names>Lukasz</given-names></name></contrib><contrib contrib-type="author"><name><surname>Chamienia</surname><given-names>Andrzej</given-names></name></contrib><contrib contrib-type="author"><name><surname>Debska-Slizien</surname><given-names>Alicja</given-names></name></contrib><contrib contrib-type="author"><name><surname>Aleksandrowicz</surname><given-names>Ewa</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mysliwska</surname><given-names>Jolanta</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rutkowski</surname><given-names>Boleslaw</given-names></name></contrib></contrib-group><aff>Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdansk, ul. Debinki 7, 80-211 Gdansk, Poland.</aff><pub-date pub-type="ppub"><month>12</month><year>2004</year></pub-date><volume>13</volume><issue>5-6</issue><fpage>377</fpage><lpage>380</lpage><abstract><p>BACKGROUND: Ozone as a strong oxidant may induce an inflammatory response. AIM: The hypothesis was verified as to whether ozonated autohemotherapy using an ozone dose in therapeutic range changes the plasma concentration of C-reactive protein and interleukin-6, markers of inflammation. METHODS: In a controlled, single-blind, cross-over study, 12 chronically hemodialyzed patients with peripheral arterial disease were exposed to nine sessions of autohemotherapy with blood exposure to oxygen as a control followed by nine sessions of ozonated autohemotherapy with an ozone concentration of 50 microg/ml. RESULTS: There was no statistical difference between C-reactive protein levels at baseline (1.53 +/- 1.01 mg/l), after nine sessions of control autohemotherapy (1.48 +/- 0.96 mg/l), and after nine sessions of ozonated autohemotherapy (1.55 +/- 0.84 mg/l). There was also no statistical difference between the interleukin-6 serum concentration at baseline (438 +/- 118 pg/ml), after nine sessions of control autohemotherapy (444 +/- 120 pg/ml), and after nine sessions of ozonated autohemotherapy (466 +/- 152 pg/ml). CONCLUSION: The results of this study suggest that ozonated autohemotherapy using an ozone concentration of 50 microg/ml does not induce an inflammatory response.</p></abstract></article-meta></front></article>

